School of Pharmacy leads in NIH funding for the 44th straight year

In 2023, and for the 44th consecutive year, the UCSF School of Pharmacy received more research funding from the National Institutes of Health (NIH) than any other pharmacy school in the country. School researchers netted $36,769,061 million to fuel their efforts spanning drug discovery, bioengineering, pharmacokinetics, clinical pharmacy, and more.

© majedphoto.com

The funds include 65 grants spread across the School’s Department of Pharmaceutical Chemistry, Department of Bioengineering and Therapeutic Sciences, and Department of Clinical Pharmacy; the UCSF Quantitative Biosciences Institute (QBI), an Organized Research Unit in the School; as well as the UCSF-Stanford Center of Excellence in Regulatory Science and Innovation (CERSI), housed in the Department of Bioengineering and Therapeutic Sciences.

UCSF as a whole received $789,196,651 million in NIH funds and ranked second among all public and private U.S. universities, after Johns Hopkins University. Leidos Biomedical Research, Inc., which administers research contracts for the National Cancer Institute’s Frederick National Laboratory for Cancer Research, was the largest recipient overall, receiving $866 million.

School rankings are compiled by the independent Blue Ridge Institute for Medical Research, based on the most current NIH data.

“Our faculty continues to collaborate and innovate in pursuing our mission of expanding research, education, and clinical care,” said Dean Kathy Giacomini, PhD, BSPharm. “These grants make it possible to maintain our global leadership in biomedical advances and improving health care outcomes.”

Top School recipients of NIH funds

Nevan Krogan, PhD, Department of Cellular and Molecular Pharmacology, $11,566,855

Nevan Krogan, PhD, director of the School’s Quantitative Biosciences Institute (QBI), is developing experimental and computational tools that allow for effective connections between discovery research and the clinical world, enabling novel therapies for diseases.

Sook Wah Yee, PhD, Department of Bioengineering and Therapeutic Sciences, $3,515,337

© majedphoto.com

Sook Wah Yee, PhD

Sook Wah Yee, PhD, is actively involved in the Pharmacogenomics Global Research Network (PGRN), enhancing scientific exchange and expanding the boundaries of understanding drug response within the context of precision medicine.

Kathy Giacomini, PhD, BSPharm, Department of Bioengineering and Therapeutic Sciences, $2,378,691

In addition to setting the School’s strategic agenda and ensuring that it has the resources and organizational structure required to succeed in its mission, Kathy Giacomini, PhD, BSPharm, focuses on drugs used in the treatment of diseases associated with metabolic syndrome and aims to advance the field of regulatory sciences while improving the development and evaluation of diagnostics, therapeutics, and medical devices.

Rada Savic, PhD, Department of Bioengineering and Therapeutic Sciences, $2,027,487

Rada Savic, PhD, investigates optimal drug discovery and development approaches using computational methods, integrating data and knowledge to determine the optimal choices of precise and personalized treatments.

Zev Gartner, PhD, Department of Pharmaceutical Chemistry, $1,609,551

Elisabeth Fall

Zev Gartner, PhD

Zev Gartner, PhD, works to understand how cells self-organize into tissues, how the structure of tissues helps regulate cell behaviors, and how tissue structure breaks down in diseases like cancer. He focuses on speeding the development of new drugs and developing new strategies for regenerative medicine.

More

UCSF Tops Public Universities in NIH Research Funding in 2023